ILMN

Illumina, Inc.

Technology
162.55 -1.85 -1.13% Market Closed
2026-06-02 • USD

Key Metrics

Market Cap 24.59B
EV —
Shares Out 151.30M
Revenue (ttm) —
Net Income 933.00M
Beta —
P/E 32.38
Forward P/E —
EPS (ttm) $6.06
P/S —
P/B 9.29
P/FCF —
P/C —
EV/Sales —
EV/EBITDA —
ROA 14.22%
ROE 37.82%
ROIC —
Gross Margin —
Oper. Margin —
Profit Margin —
Debt/Eq 0.21
LT Debt/Eq —
Quick Ratio —
Current Ratio 1.75
Book/sh 17.49
Cash/sh —
Div Yield —
Div TTM —
Payout Ratio —
SMA20 10.59%
SMA50 20.13%
SMA200 32.27%
Volume 2,132,767
Avg Volume 1.86M
Rel Volume —
Perf Week -0.25%
Perf Month 16.88%
Perf Quarter 26.75%
Perf Half Y 26.05%
Perf YTD 23.93%
Perf Year 97.63%
Perf 3Y -20.56%
Perf 5Y -60.00%

Factor Lens

Seasonal Performance

Financial Trends

Revenue & Net Income

Earnings Per Share

Margins

Cash Flow

Company Overview

Illumina, Inc. is a global leader in sequencing- and array-based solutions for genetic and genomic analysis. The company develops and markets integrated sequencing and microarray systems, consumables, and analysis tools designed to accelerate and simplify genetic analysis across a range of genomic complexity, price points, and throughput. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical companies, biotechnology firms, commercial molecular diagnostic laboratories, and consumer genomics companies. The company's portfolio includes DNA sequencing platforms (ranging from benchtop MiSeq systems to production-scale NovaSeq X platforms), informatics solutions (BaseSpace, DRAGEN, Illumina Connected Analytics), and consumables such as reagents and library preparation kits. Products are used for research and clinical applications including whole-genome sequencing, targeted resequencing, gene expression analysis, reproductive health testing, cancer genomics, and rare disease diagnosis. The company operates in research and applied markets (academic research, biotechnology, pharmaceutical, consumer genomics, agrigenomics) and clinical markets (oncology, genetic health, reproductive health). On June 24, 2024, the company completed the spin-off of GRAIL, Inc. and retains approximately 14.5% ownership.

Name
Illumina, Inc.
Industry
Technology
CEO
Jacob Thaysen · Chief Executive Officer
Employees
7,500 as of 2025-12-28
IPO Date
2018-11-05
Phone
(858) 202-4500
Address
5200 Illumina Way, San Diego, CA 92122
Website
www.illumina.com

Key Executives

Name Title FY Pay
Patricia Leckman Chief People Officer —
Ankur Dhingra Chief Financial Officer —
Scott Davies Chief Legal Officer —
Steven Barnard Chief Technology Officer —
Jacob Thaysen Chief Executive Officer —

Latest News